Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: An exploratory analysis of a single-blind randomized trial

Depression and Anxiety

Volumn 29, Issue 2, 2012, Pages 111-122

  Davis, Lori L ^a,b   Pilkinton, Patricia ^a   Wisniewski, Stephen R ^c,d   Trivedi, Madhukar H ^e   Gaynes, Bradley N ^f   Howland, Robert H ^d   Zisook, Sidney ^g   Balasubramani, G K ^c   Fava, Maurizio ^h   Rush, A John ⁱ  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Combination antidepressants; Dual diagnosis; Major depressive disorder; Substance use disorder; Treatment outcome

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; MIRTAZAPINE; PLACEBO; VENLAFAXINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE BLIND PROCEDURE; SUBSTANCE ABUSE; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT RESPONSE;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; BUPROPION; CHRONIC DISEASE; CITALOPRAM; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DUAL (PSYCHIATRY); DRUG THERAPY, COMBINATION; HUMANS; MIANSERIN; RECURRENCE; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; SUICIDE, ATTEMPTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859876704     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20918     Document Type: Article

References (59)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National comorbidity survey replication (NCS-R). JAMA 2003;289:3095-3105. (Pubitemid 37432885)
2. Chang CK, Hayes RD, Broadbent M, et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry 2010;10:77.
3. Davis LL, Rush JA, Wisniewski SR, et al. Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the sequence treatment alternatives to relieve depression cohort. Compr Psychiatry 2005;46:81-89. (Pubitemid 40249874)
4. Davis LL, Frazier E, Husain MM, et al. Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. Am J Addict 2006;15:278-285. (Pubitemid 44174488)
5. Davis LL, Frazier E, Gaynes BN, et al. Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort. J Clin Psychiatry 2007;68:1931-1938.
6. Davis LL, Wisniewski SR, Howland RH, et al. Does comorbid substance use disorder impair recovery from major depression with SSRI Treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend 2010;107:161-170.
7. Hatsukami D, Pickens RW. Posttreatment depression in an alcohol and drug abuse population. Am J Psychiatry 1982;139:1563-1566. (Pubitemid 13204453)
8. Schuckit MA. Alcohol and depression: a clinical perspective. Acta Psychiatrica Scandanavia 1994;377:28-32. (Pubitemid 24147801)
9. Schuckit, MA. Drug and Alcohol Abuse: A Clinical Guide to Diagnosis and Treatment. (5th ed.) New York: Kluwer Academic/Plenum Publishers; 2000.
10. Sedlacek DA, Miller SI. A framework for relating alcoholism and depression. J Fam Pract 1982;14:41-44.
11. Ostacher MJ. Comorbid alcohol and substance abuse dependence in depression: impact on the outcome of antidepressant treatment. Psychiatr Clin North Am 2007;30:69-76. (Pubitemid 46386306)
12. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004;291:1887-1896. (Pubitemid 38509503)
13. Howland RH, Rush AJ, Wisniewski SR, et al. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend 2009;99:248-260.
14. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and longterm outcomes: a single-blind randomized study. Am J Psychiatry 2011;168:689-701.
15. Depression Guideline Panel, 1993. Clinical Practice Guideline, Number 5: Depression in Primary Care: Volume 2. Treatment of Major Depression, Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, Rockville, MD, USA.
16. American Psychiatric Association. Diagnostic and statistical manual ofmental disorders. (4th ed.), text revision. Washington, D.C.: American Psychiatric Press; 2000.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-61.
18. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008;65:342-351. (Pubitemid 351704490)
19. Zimmerman M, Mattia JI. A self-report scale to help make psychiatric diagnoses: the psychiatric diagnostic screening questionnaire. Arch Gen Psychiatry 2001a;58:787-794. (Pubitemid 32717805)
20. Zimmerman M, Mattia JI. The psychiatric diagnostic screening questionnaire: development, reliability and validity. Compr Psychiatry 2001b;42:175-189. (Pubitemid 32410920)
21. Rush AJ, Zimmerman M, Wisniewski SR, et al. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord 2005;87:43-55. (Pubitemid 40828202)
22. Sangha O, Stucki G, Liang MH, et al. The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003;49:156-163. (Pubitemid 36418272)
23. Rush AJ, Gullion CM, Basco MR, et al. The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med 1996;26:477-486. (Pubitemid 26142491)
24. Rush AJ, Carmody TJ, Reimitz PE. The inventory of depressive symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Method Psychiatric Res 2000;9:45-59.
25. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-583. (Pubitemid 37289444)
26. Trivedi MH, Wisniewski SR, Morris DW, et al. Concise health risk tracking (CHRT) scale: a brief self-report and clinician-rating of suicidal risk. J Clin Psych 2011;72:757-764.
27. Altman EG, Hedeker D, Peterson JL, et al. The Altman self-rating mania scale. Biol Psychiatry 1997;42:948-955. (Pubitemid 27486450)
28. Correa R, Akiskal H, Gilmer W, et al. Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression?? J Affect Disord 2010;127:10-18.
29. Zimmerman M, Mattia JI. A self-report scale to help make psychiatric diagnoses: the psychiatric diagnostic screening questionnaire. Arch Gen Psychiatry 2001a;58:787-794. (Pubitemid 32717805)
30. Zimmerman M, Mattia JI. The psychiatric diagnostic screening questionnaire: development, reliability and validity. Compr Psychiatry 2001b;42:175-189. (Pubitemid 32410920)
31. Magruder KM, Sonne SC, Brady KT, et al. Screening for co-occurring mental disorders in drug treatment populations. J Drug Issues 2005;35:593-605. (Pubitemid 41393191)
32. Zimmerman M, Sheeran T, Chelminski I, Young D. Screening for psychiatric disorders in outpatients with DSM-IV substance use disorders. J Subst Abuse Treat 2004;26:181-188. (Pubitemid 38452837)
33. Rush AJ, Zimmerman M, Wisniewski SR, et al. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord 2005;87:43-55. (Pubitemid 40828202)
34. Trivedi MH, Rush AJ, Wisniewski SR, et al. STAR*D study team evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40. (Pubitemid 43050100)
35. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend 2007;88:S61-S71. (Pubitemid 46528065)
36. Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology 2007;32:2479-2489. (Pubitemid 350126843)
37. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 2006;59:493-501. (Pubitemid 43320536)
38. Wisniewski SR, Rush AJ, Balasubramani GK, et al. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract 2006;12:71-79. (Pubitemid 44284089)
39. Wisniewski SR, Eng H, Meloro L, et al. Web-based communications and management of a multi-center clinical trial: the sequenced treatment alternatives to relieve depression (STAR*D) project. Clin Trials 2004;1:87-398.
40. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62:S4-S11.
41. Leuchter AF, Lesser IM, Trivedi MH, et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J Psychiatr Pract 2008;14:271-280.
42. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006;163:1531-1541. (Pubitemid 44465752)
43. Mundt JC, Marks IM, Shear MK, et al. The work and social adjustment scale: a simple measure of impairment in functioning. Br J Psychiatry 202;180:461-464.
44. Frisch MB. Manual and Treatment Guide for the Quality of Life Inventory. Minneapolis, MN: National Computer Systems, Inc.; 1994.
45. Frisch MB, Clark MP, Rouse SV, et al. Predictive and treatment validity of life satisfaction and the quality of life inventory. Assessment 2005;12:66-78. (Pubitemid 40900463)
46. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986;22:343-381. (Pubitemid 16043808)
47. Levine J, Schooler NR. General versus specific inquiry with SAFTEE. J Clin Psychopharmacol 1992;12:448.
48. Fava M, Iosifescu DV, Pedrelli P, et al. Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychother Psychosom 2009;78:91-97.
49. Fava M, Abraham M, Alpert J, et al. Gender differences in Axis I comorbidity among depressed outpatients. J Affect Disord 1996;38:129-133. (Pubitemid 26191497)
50. McDermut W, Mattia J, Zimmerman M. Comorbidity burden and its impact on psychosocial morbidity in depressed outpatients. J Affect Disord 2001;65:289-295. (Pubitemid 32757160)
51. Melartin TK, Rytsala HJ, Leskela US, et al. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa depression study. J Clin Psychiatry 2002;63:126-134. (Pubitemid 34173849)
52. Salloum IM, Mezzich JE, Cornelius J, et al. Clinical profile of comorbid major depression and alcohol use disorders in an initial psychiatric evaluation. Compr Psychiatry 1995;36:260-266.
53. Pettinati HM, Oslin DV, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010;167:668-675.
54. Bossarte RM, Swahn MH. The associations between early alcohol use and suicide attempts among adolescents with a history of major depression. Addict Behav 2011;36:532-535.
55. Sher L, Stanley BH, Harkavy-Friedman JM, et al. Depressed patients with co-occurring alcohol use disorder: a unique patient population. J Clin Psychiatry 2008;69:907-915. (Pubitemid 351944942)
56. Kuo PH, Neale MC, Walch D, et al. Genome wide linkage scans for major depression in individuals with alcohol dependence. J Psychiatr Res 2010;44:616-619.
57. Nurnberger JI, Fofoud T, Flury L, et al. Evidence for a locus on chromosome 1 that influences vulnerability to alcoholism and affective disorder. Am J Psychiatry 2001;158:718-724. (Pubitemid 32429838)
58. Statham DJ, Heath AC, Madden PA, et al. Suicidal behavior: an epidemiological and genetic study. Psychol Med 1998;28:839-855. (Pubitemid 28393563)
59. Lin N, Eisen SA, Scherrer JF, et al. The influence of familial and non-familial factors on the association between major depression and substance abuse/dependence in 1874 monozygotic male twin pairs. Drug Alcohol Depend 1996;43:49-55. (Pubitemid 26382198)